HQY

$79.40

Market ClosedAs of Mar 17, 8:00 PM UTC

HealthEquity, Inc.

Recent News

Motley Fool
Mar 17, 2026

HealthEquity (HQY) Q4 2026 Earnings Transcript

This is HealthEquity, Inc.'s fourth quarter fiscal 2026 earnings conference call. Before I turn the call over to Scott for our prepared remarks, we note that the press release announcing our fourth quarter financial results was issued after the market closed this afternoon, and that it includes certain non-GAAP financial measures that we will reference here today.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

Compared to Estimates, HealthEquity (HQY) Q4 Earnings: A Look at Key Metrics

The headline numbers for HealthEquity (HQY) give insight into how the company performed in the quarter ended January 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates

HealthEquity (HQY) delivered earnings and revenue surprises of +7.09% and +0.52%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Mar 17, 2026

HealthEquity: Fiscal Q4 Earnings Snapshot

The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 89 cents per share. The provider of services for managing health care accounts posted revenue of $334.6 million in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $332.8 million.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 15, 2026

Assessing HealthEquity (HQY) Valuation As Fiscal Q4 Earnings Approach

HealthEquity earnings in focus HealthEquity (HQY) heads into its upcoming fiscal Q4 report with investors watching whether the company can again exceed expectations, as analysts look for strong EPS growth alongside more moderate revenue gains. See our latest analysis for HealthEquity. At a share price of US$77.81, HealthEquity has a 30 day share price return of 5.32% but a year to date share price decline of 14.56%, alongside a 1 year total shareholder return decline of 20.12% and a 3 year...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.